Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | FABP4 | P15090 | 3/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.41 |
| ▸ | PPARG | P37231 | 1/20 | 0.41 |
| ▸ | PPARD | Q03181 | 1/20 | 0.41 |
| ▸ | PPARA | Q07869 | 1/20 | 0.41 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | ALB | P02768 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5726846 | 0.99 | MAPT (0.44) | MAPTFABP4MCL1FFAR1PPARG | |
| SCHEMBL5725191 | 0.96 | FABP4 (0.44) | MAPTFABP4MCL1FFAR1PPARG | |
| SCHEMBL14276974 | 0.90 | MAPT (0.46) | MAPTBDKRB1KDM4ETHRB | |
| SCHEMBL5725882 | 0.89 | FFAR1 (0.52) | MAPTFABP4MCL1FFAR1PPARG | |
| SCHEMBL5726952 | 0.88 | KDM4E (0.56) | FFAR1PPARGPPARDBDKRB1KDM4E | |
| SCHEMBL5726848 | 0.88 | MAPT (0.43) | MAPTPPARGPPARABDKRB1KDM4E | |
| SCHEMBL5725093 | 0.86 | FFAR1 (0.42) | FABP4MCL1FFAR1PPARGPPARD | |
| SCHEMBL14307289 | 0.86 | MAPT (0.49) | MAPTTHRB | |
| SCHEMBL5726053 | 0.85 | MAPT (0.43) | MAPTMCL1FFAR1PPARGPPARD | |
| SCHEMBL5725014 | 0.85 | FFAR1 (0.41) | FFAR1PPARGPPARDPPARAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 94 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11666626-B2 | Antimicrobial articles produced by additive manufacturing | ORTHOPAEDIC INNOVATION CENTRE INC. (CA) | 2023-06-06 | — | — | US | claimed |
| US-20210113651-A1 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | ORTHOPAEDIC INNOVATION CENTRE INC (US) | 2021-04-22 | — | — | US | claimed |
| US-10905740-B2 | Antimicrobial articles produced by additive manufacturing | ORTHOPAEDIC INNOVATION CENTRE INC. (CA) | 2021-02-02 | — | — | US | claimed |
| EP-3122393-B1 | SELECTIVE LASER SINTERING PROCESS (SLS) FOR PRODUCING ANTIBIOTIC-ELUTING MEDICAL IMPLANTS | ORTHOPAEDIC INNOVATION CENTRE INC (CA) | 2020-04-22 | — | — | EP | claimed |
| US-20200061239-A1 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | ORTHOPAEDIC INNOVATION CENTRE INC (CA) | 2020-02-27 | — | — | US | claimed |
| US-10406263-B2 | Antimicrobial articles produced by additive manufacturing | ORTHOPAEDIC INNOVATION CENTRE INC. (CA) | 2019-09-10 | — | — | US | claimed |
| EP-2919823-B1 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | ORTHOPAEDIC INNOVATION CENTRE INC (CA) | 2019-07-03 | — | — | EP | claimed |
| CN-109453433-A | Pass through the antimicrobial article of addition manufacture production | 整形外科创新中心公司 | 2019-03-12 | — | — | CN | claimed |
| US-20170095596-A1 | ANTIMICROBIAL ARTICLES PRODUCED BY ADDITIVE MANUFACTURING | ORTHOPAEDIC INNOVATION CENTRE (CA) | 2017-04-06 | — | — | US | claimed |
| CN-106456835-A | Antimicrobial articles produced by additive manufacturing | 整形外科创新中心公司 | 2017-02-22 | — | — | CN | claimed |
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | CAMERON KIMBERLY O (US) | 2002-02-07 | — | — | US | claimed |
| US-6344485-B1 | Method for treating glaucoma | PFIZER INC. | 2002-02-05 | — | — | US | claimed |
| US-6288120-B1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | PFIZER INC. | 2001-09-11 | — | — | US | claimed |
| EP-1108426-A2 | Use of prostaglandin agonists to treat erectile dysfunction or impotence | Pfizer Products Inc. (US) | 2001-06-20 | — | — | EP | claimed |
| JP-2000507961-A | — | — | 2000-06-27 | — | — | JP | claimed |
| EP-1000619-A2 | Method for treating glaucoma | Pfizer Products Inc. (US) | 2000-05-17 | — | — | EP | claimed |
| EP-0951282-A1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER INC. (US) | 1999-10-27 | — | — | EP | claimed |
| EP-0946501-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1999-10-06 | — | — | EP | claimed |
| WO-1998027976-A1 | PREVENTION AND TREATMENT OF SKELETAL DISORDER WITH EP2 RECEPTOR SUBTYPE SELECTIVE PROSTAGLANDIN E2 AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | claimed |
| WO-1998028264-A1 | PREVENTION OF LOSS AND RESTORATION OF BONE MASS BY CERTAIN PROSTAGLANDIN AGONISTS | PFIZER INC. (US) | 1998-07-02 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016368-A1 | Prevention of loss and restoration of bone mass by certain prostaglandin agonists | HPGDS, PTGIR, PTGER1 | MAPT 4871/4885FABP4 221/4885MCL1 2299/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.